Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hunter

Showing results (1211-1220 of 1,249) with videos related to

Pageof 125
Sort By:
Blood|January 25, 2008
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemiaAllen W Ho, Evdoxia Hatjiharissi, Bryan T Ciccarelli, et al.
Blood|November 5, 2008
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemiaXavier Leleu, Lian Xu, Xiaoying Jia, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disordersDaniel Ditzel Santos, Evdoxia Hatjiharissi, Olivier Tournilhac, et al.
Plos One|January 14, 2014
Improved metabolic health alters host metabolism in parallel with changes in systemic xeno-metabolites of gut originCaitlin Campbell, Dmitry Grapov, Oliver Fiehn, et al.
Blood|January 17, 2013
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionLian Xu, Zachary R Hunter, Guang Yang, et al.
Frontiers in Cell and Developmental Biology|October 11, 2021
Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease ControlJemma Nicholls, Benjamin Cao, Laetitia Le Texier, et al.
Blood|March 3, 2018
BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanismJiaji G Chen, Xia Liu, Manit Munshi, et al.
Experimental Hematology & Oncology|September 12, 2022
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström MacroglobulinemiaEugenio Morelli, Zachary R Hunter, Mariateresa Fulciniti, et al.
British Journal of Haematology|November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinibJorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.
Leukemia|September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Pageof 125

Showing results (1211-1220 of 1,249) with videos related to

Sort By:
Pageof 125
Blood|January 25, 2008
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemiaAllen W Ho, Evdoxia Hatjiharissi, Bryan T Ciccarelli, et al.
Blood|November 5, 2008
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemiaXavier Leleu, Lian Xu, Xiaoying Jia, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disordersDaniel Ditzel Santos, Evdoxia Hatjiharissi, Olivier Tournilhac, et al.
Plos One|January 14, 2014
Improved metabolic health alters host metabolism in parallel with changes in systemic xeno-metabolites of gut originCaitlin Campbell, Dmitry Grapov, Oliver Fiehn, et al.
Blood|January 17, 2013
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionLian Xu, Zachary R Hunter, Guang Yang, et al.
Frontiers in Cell and Developmental Biology|October 11, 2021
Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease ControlJemma Nicholls, Benjamin Cao, Laetitia Le Texier, et al.
Blood|March 3, 2018
BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanismJiaji G Chen, Xia Liu, Manit Munshi, et al.
Experimental Hematology & Oncology|September 12, 2022
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström MacroglobulinemiaEugenio Morelli, Zachary R Hunter, Mariateresa Fulciniti, et al.
British Journal of Haematology|November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinibJorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.
Leukemia|September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Pageof 125